Reductions in glycaemia and weight with once-weekly dosing of LY2189265, a long-acting glucagon-like peptide 1 (GLP-1) analogue in patients with type 2 diabetes mellitus

被引：0
|
作者：
Hardy, T. A. [1 ]
Barrington, P. [2 ]
Chien, J. [1 ]
Showalter, H. [1 ]
Schneck, K. [1 ]
Cui, S.
Tibaldi, F. [3 ]
Ellis, B. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Windlesham, Surrey, England
[3] GSK Biol, Rixensart, Belgium
来源：
DIABETOLOGIA | 2009年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
731
引用
收藏
页码：S286 / S286
页数：1
相关论文
共 50 条
  • [41] Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus
    Mannucci, E
    Ognibene, A
    Cremasco, F
    Bardini, G
    Mencucci, A
    Pierazzuoli, E
    Ciani, S
    Fanelli, A
    Messeri, G
    Rotella, CM
    DIABETIC MEDICINE, 2000, 17 (10) : 713 - 719
  • [42] Long-Acting Glucagon-Like Peptide-1 (GLP-1) Agonist Therapy in Post Solid Organ Transplant Patients.
    Krisl, J.
    Gaber, A.
    Sadhu, A.
    TRANSPLANTATION, 2014, 98 : 523 - 524
  • [43] An investigation into the efficacy of glucagon-like peptide 1 (GLP-1) analogues in obese patients with Type 1 diabetes
    Shah, M. K.
    Danjuma, M.
    Saeed, T.
    Khan, E. G.
    DIABETIC MEDICINE, 2014, 31 : 178 - 178
  • [44] The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
    Brice, Kira R.
    Tzefos, Maria K.
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2011, 4 : 13 - 24
  • [45] Glucagon-like peptide-1 (GLP-1) in obese subjects with and without type 2 diabetes
    Rotella, CM
    Ognibene, A
    Cremasco, F
    Bardini, G
    Mencucci, A
    Pierazzuoli, E
    Ciani, S
    Messeri, G
    Mannucci, E
    DIABETES, 2000, 49 : A1 - A1
  • [46] Efpeglenatide Glucagon-like peptide 1 (GLP-1) receptor agonist Treatment for type 2 diabetes
    Reid, J.
    Rana, K.
    Segel, S. A.
    Sheikh-Ali, M.
    Choksi, R. R.
    Goldfaden, R. F.
    DRUGS OF THE FUTURE, 2019, 44 (06) : 435 - 441
  • [47] Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes
    Nauck, MA
    Holst, JJ
    Willms, B
    Schmiegel, W
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1997, 105 (04) : 187 - 195
  • [48] Liraglutide: A once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus
    Joffe, David
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (16) : 1326 - 1336
  • [49] Pharmacokinetics and Pharmacodynamics of Long-Acting GLP-2 Analogue Glepaglutide after Once-weekly Dosing in Adult Healthy Subjects
    Sonne, K.
    Knudsen, K.
    Mathiesen, Mosolff J.
    Rasmussen, Koefoed G.
    Berner-Hansen, M.
    TRANSPLANTATION, 2021, 105 (7S) : S37 - S37
  • [50] Long-Acting GLP-1 and Glucagon Receptor Dual Agonists for the Treatment of Type 2 Diabetes
    You, Seohee
    Mcdonald, Mary
    Case, Martin
    Steiner, Derek
    Tat, Timothy
    Jenkinson, Celia
    Pick, Rebecca
    Hart, Juliet
    Moreno, Veronica
    Parise, Jason
    Yan, Wen
    Camacho, Raul
    Swanson, Ronald
    Chi, Ellen
    Demarest, Keith
    Leonard, James
    DIABETES, 2016, 65 : A274 - A274
12345